473 related articles for article (PubMed ID: 8573710)
1. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.
Jordan VC
Breast Cancer Res Treat; 1995; 36(3):267-85. PubMed ID: 8573710
[TBL] [Abstract][Full Text] [Related]
2. Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
Dhingra K
Cancer Invest; 2001; 19(6):649-59. PubMed ID: 11486708
[TBL] [Abstract][Full Text] [Related]
3. Basic guide to the mechanisms of antiestrogen action.
MacGregor JI; Jordan VC
Pharmacol Rev; 1998 Jun; 50(2):151-96. PubMed ID: 9647865
[TBL] [Abstract][Full Text] [Related]
4. Alternate antiestrogens and approaches to the prevention of breast cancer.
Jordan VC
J Cell Biochem Suppl; 1995; 22():51-7. PubMed ID: 8538210
[TBL] [Abstract][Full Text] [Related]
5. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
6. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
7. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
[TBL] [Abstract][Full Text] [Related]
8. The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.
Jordan VC; Obiorah I; Fan P; Kim HR; Ariazi E; Cunliffe H; Brauch H
Breast; 2011 Oct; 20 Suppl 3(Suppl 3):S1-11. PubMed ID: 22015273
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer prevention by antiestrogens.
Osborne MP
Ann N Y Acad Sci; 1999; 889():146-51. PubMed ID: 10668491
[TBL] [Abstract][Full Text] [Related]
10. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
11. Antiestrogens--tamoxifen, SERMs and beyond.
Dhingra K
Invest New Drugs; 1999; 17(3):285-311. PubMed ID: 10665480
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen, raloxifene and the prevention of breast cancer.
Bentrem DJ; Craig Jordan V
Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
[TBL] [Abstract][Full Text] [Related]
13. Progress in the prevention of breast cancer: concept to reality.
Jordan VC
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):269-77. PubMed ID: 11162935
[TBL] [Abstract][Full Text] [Related]
14. The role of tamoxifen in the treatment and prevention of breast cancer.
Jordan VC
Curr Probl Cancer; 1992; 16(3):129-76. PubMed ID: 1582240
[TBL] [Abstract][Full Text] [Related]
15. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.
Bergman L; Beelen ML; Gallee MP; Hollema H; Benraadt J; van Leeuwen FE
Lancet; 2000 Sep; 356(9233):881-7. PubMed ID: 11036892
[TBL] [Abstract][Full Text] [Related]
16. Pure antiestrogens as a new therapy for breast cancer.
England GM; Jordan VC
Oncol Res; 1997; 9(8):397-402. PubMed ID: 9436192
[TBL] [Abstract][Full Text] [Related]
17. Status of antiestrogen breast cancer prevention trials.
Powles TJ
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):28-31. PubMed ID: 9556788
[TBL] [Abstract][Full Text] [Related]
18. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
19. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Robertson JF
Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen therapy--long-term results and complications.
Moore MP; Kinne DW
Adv Surg; 1996; 29():263-9. PubMed ID: 8720007
[No Abstract] [Full Text] [Related]
[Next] [New Search]
